vatiquinone

News

PTC stung by FDA decision not to approve rare disease drug

It looks like PTC will have to carry out another trial of its drug for Friedreich ataxia before the FDA will consider approval.

News

PTC slides on failed Friedreich ataxia study

PTC Therapeutics has cued up no fewer than three clinical trial readouts this quarter that could lead to new regulatory filings – but the latest for vatiquinone in inherited nerve dis

News

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks